Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226895 · ClinicalTrials.gov registry record · Phase 1
A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis
A Phase 1 study of Clinical High Risk for Psychosis (CHR), sponsored by Monument Therapeutics Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 15
- Study locations
NCT07226895: Recruiting Phase 1 study of Clinical High Risk for Psychosis (CHR), sponsored by Monument Therapeutics Limited.
NCT07226895 is a Phase 1 study of Clinical High Risk for Psychosis (CHR) that is actively recruiting participants, run by Monument Therapeutics Limited. The registered enrollment target is 150 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (150% higher). The trial reports 15 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07226895, a Phase 1 study of Clinical High Risk for Psychosis (CHR), is actively recruiting participants, sponsored by Monument Therapeutics Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 15
- Study locations
Study Summary
The goal of this clinical trial is to learn how tests undertaken by people at high risk of developing psychosis (aged 17 to 30 years old) change when those people are given the study drug MT1988 daily for 8 weeks. This will help identify tests that could be used in later trials developing treatments for symptoms in people at high risk of developing psychosis, to measure whether those new treatments are effective. The main question this trial aims to answer is: Can any of the tests (biomarkers) used in this study detect changes in participants dosed with one of two different dose levels of MT1988? Researchers will compare the results from two dose levels of MT1988 to a placebo group. Researchers do not expect to see the test results change in participants taking placebo and this will be compared to changes expected in test results in participants taking MT1988. Participants will: * take a dose of MT1988 or placebo twice per day for 8 weeks * attend clinic appointments every two weeks to undertake assessments * report any side effects they experience to the researchers
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MT1988 Low Dose
- DRUG MT1988 High Dose
Study Locations (15)
California
- University of California, Irvine - Irvine
- University of California - Los Angeles
- University of California, San Francisco - San Francisco
New York
- Northwell Health - Glen Oaks
- Columbia University - New York
- Icahan School of Medicine at Mount Sinai - New York
Pennsylvania
- University of Pennsylvania - Philadelphia
- Temple University - Philadelphia
- University of Pittsburgh School of Medicine - Pittsburgh
Connecticut
- Yale University Conneticut Mental Health Center - New Haven
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Missouri
- Washington University - St Louis
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Ohio
- Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-03 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
What NCT07226895 shows while recruiting
NCT07226895 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (150% higher).
The record links to 1 condition, with Clinical High Risk for Psychosis (CHR) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07226895 lists 15 locations in 9 states (California, New York, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT07226895 about?
NCT07226895 is a clinical study titled "A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis". The goal of this clinical trial is to learn how tests undertaken by people at high risk of developing psychosis (aged 17 to 30 years old) change when those people are given the study drug MT1988 daily for 8 weeks. This will help identify tests that could be used in later trials developing treatments...
What is the current status of trial NCT07226895?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2026-03. Estimated completion is 2027-04.
What conditions does trial NCT07226895 study?
This clinical trial studies the following conditions: Clinical High Risk for Psychosis (CHR).
What interventions are being tested in trial NCT07226895?
The interventions under investigation include: Placebo (DRUG), MT1988 Low Dose (DRUG), MT1988 High Dose (DRUG).
Who is sponsoring clinical trial NCT07226895?
This trial is sponsored by Monument Therapeutics Limited, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07226895 being conducted?
This trial has 15 study locations across California, Connecticut, Massachusetts, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clinical High Risk for Psychosis (CHR)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07226895's enrollment target sits among peer trials
150 363rd of 2000 higher than 1,620 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia